Automated liquid handlers are great for increasing assay efficiency and throughput while also improving accuracy, precision and trueness, so it can be surprising to find critical medical tests that are still being done manually. One area where the gold standard—the microdilution test—uses a manual method is evaluating bacterial sensitivity to antibiotics. Because of the time, effort, and complexity of the microdilution test, most hospital-based clinics need to send patient samples to a reference lab for analysis, which leads to a significant delay in the results. James Kirby, MD, Director of the Clinical Microbiology Laboratory at BIDMC and Associate Professor of Pathology at Harvard Medical School, is working to change the situation by automating the test so that it is faster and can be performed by personnel in a hospital clinic1.
Typically, when a patient is diagnosed with a bacterial infection, the physician will determine which antibiotic to start with by evaluating the patient’s symptoms and making an educated guess about the identity of the bacteria. In the meantime, a patient sample is sent out to a reference lab to test for susceptibility to various antibiotics, which can add four- to six days to the process. This delay between initial diagnosis of a bacterial infection and determination of the most effective antibiotic to use is often referred to as the “antimicrobial testing gap.”
In the past, the microdilution test would often verify the physician’s original treatment choice, minimizing the impact of the delay in receiving the results. However, the increased spread of multi-drug-resistant bacteria has made the consequences of the antimicrobial testing gap more severe, as a physician’s initial antibiotic choice is increasingly the wrong one.
In an effort to shorten the antimicrobial testing gap, Dr. Kirby and colleagues have automated and miniaturized the standard broth microdilution protocol (used to test the susceptibility of bacteria to antibiotics) using the same digital dispensing technology employed by ink jet printers—specifically, an HP D300 digital dispensing system. Their modified assay greatly simplifies the complexity of the process, reducing the labware need and setup time so that the microdilution test can now be performed in most hospital-based clinical labs. At the same time, the accuracy of the new method is the same as that for the standard assay, while the precision has been increased, improving overall assay quality. Lastly, because the test is now in a 384-well format, throughput is also much greater, adding to a reduction in the overall antimicrobial testing gap.
The recent paper from Dr. Kirby’s lab1 provides a proof-of-concept validation for their streamlined microdilution test, and lays the groundwork for getting this technology that shortens the antimicrobial testing gap into clinical practice and hospital-based clinical labs. In addition, it highlights how automating an assay can significantly impact delivery of patient care.
1. Smith, K. P. & Kirby, J. E. Verification of an Automated, Digital Dispensing Platform for At-Will Broth Microdilution-Based Antimicrobial Susceptibility Testing. J. Clin. Microbiol. 54, 2288–2293 (2016). PubMed PMID: 27335151